JMS Bartlett
Ontario Institute for Cancer Research(CA)
Publications by Year
Research Areas
Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, Cancer Genomics and Diagnostics, Estrogen and related hormone effects, BRCA gene mutations in cancer
Most-Cited Works
- → Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients(2014)778 cited
- → Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial(2017)51 cited
- → Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials(2012)18 cited
- → Abstract OT2-3-01: The LORIS trial: A multicentre, randomized phase III trial of standard surgery versus active monitoring in women with newly diagnosed low risk ductal carcinoma in situ(2013)16 cited
- → Abstract P1-01-01: Analytical validation of a standardized scoring protocol for Ki67: Phase-3 of an international multicenter collaboration(2016)9 cited
- → Tumour infiltrating lymphocytes and stromal CD68 in early stage HER2 positive breast cancer(2016)7 cited
- → A prospectively planned pathology study within the TEAM trial confirms that progesterone receptor expression is prognostic but is not predictive for differential response to exemestane versus tamoxifen.(2009)7 cited
- → Abstract S1-5: PIK3CA mutations are linked to PgR expression: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) pathology study.(2012)7 cited
- → Abstract S2-4: Final Results of a Prospectively Planned Biomarker Analysis: HER1-3 as Predictive Markers of Benefit from Early Treatment with Aromatase Inhibitors Versus Tamoxifen in the TEAM Pathology Sub-Study.(2010)7 cited
- → Abstract S4-6: An international Ki67 reproducibility study(2012)6 cited